INT11243

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1987
Last Reported 2011
Negated 0
Speculated 1
Reported most in Abstract
Documents 33
Total Number 35
Disease Relevance 11.18
Pain Relevance 19.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (NPY) extracellular space (NPY) extracellular region (NPY)
cell (NPY)
Anatomy Link Frequency
sympathetic 5
nerve 5
peripheral nervous system 2
cardiomyocyte 2
EPI 2
NPY (Homo sapiens)
Pain Link Frequency Relevance Heat
Neuropeptide 417 100.00 Very High Very High Very High
substance P 139 100.00 Very High Very High Very High
Enkephalin 85 100.00 Very High Very High Very High
noradrenaline 38 100.00 Very High Very High Very High
Calcitonin gene-related peptide 22 100.00 Very High Very High Very High
Somatostatin 13 100.00 Very High Very High Very High
Dopamine 11 100.00 Very High Very High Very High
Dynorphin 8 100.00 Very High Very High Very High
gABA 7 100.00 Very High Very High Very High
medulla 24 99.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 98 99.74 Very High Very High Very High
Ganglion Cysts 4 99.60 Very High Very High Very High
Apoptosis 4 99.52 Very High Very High Very High
INFLAMMATION 65 99.08 Very High Very High Very High
Hypersensitivity 139 98.78 Very High Very High Very High
Pheochromocytoma 17 98.12 Very High Very High Very High
Increased Venous Pressure Under Development 49 98.08 Very High Very High Very High
Alzheimer's Dementia 7 97.20 Very High Very High Very High
Neurogenic Inflammation 15 96.32 Very High Very High Very High
Pain 29 96.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Collectively, these findings demonstrate that NPY Y1 receptors mediate morphine's suppressive effect on NK activity and further suggest that opioid-induced increases in nucleus accumbens D1 receptor activation inhibit splenic NK activity via NPY released from the sympathetic nervous system.
Localization (released) of NPY in nucleus accumbens associated with nucleus accumbens, opioid and morphine
1) Confidence 0.78 Published 2006 Journal J. Neuroimmunol. Section Abstract Doc Link 16766046 Disease Relevance 0 Pain Relevance 0.83
Immunohistochemical studies for multiple peptide-immunoreactivities and co-localization of Met-enkephalin-Arg6-Gly7-Leu8, neuropeptide Y and somatostatin in human adrenal medulla and pheochromocytomas.
Localization (co-localization) of neuropeptide Y in adrenal medulla associated with medulla, somatostatin, neuropeptide, enkephalin and pheochromocytoma
2) Confidence 0.78 Published 1987 Journal Peptides Section Title Doc Link 2883635 Disease Relevance 0.43 Pain Relevance 0.49
Besides containing and releasing Glu, they have been shown to contain and release peptides (somatostatin, neuropeptide Y, neurokinin B, cholecystokinin, dynorphin, enkephalin), Zn(++) ion, and brain-derived neurotrophic factor (BDNF).
Localization (release) of neuropeptide Y in brain associated with dynorphin, neuropeptide, somatostatin, enkephalin and cholecystokinin
3) Confidence 0.78 Published 2006 Journal Curr Top Med Chem Section Abstract Doc Link 16787272 Disease Relevance 0.13 Pain Relevance 0.59
It is suggested that NPY is released mainly at high levels of sympathetic activity and that blood-pressure-lowering drugs acting on alpha adrenoceptors acutely influence the release of both NA and NPY-LI from sympathetic nerves in humans.
Localization (released) of NPY in sympathetic associated with noradrenaline
4) Confidence 0.77 Published 1988 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2468060 Disease Relevance 0 Pain Relevance 0.67
The nerve-evoked NPY release that is enhanced after reserpine treatment is related to remaining vasoconstrictor effects.
Localization (release) of NPY in nerve
5) Confidence 0.75 Published 1987 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2455193 Disease Relevance 0.29 Pain Relevance 0.65
Immunoreactive CGRP or NPY were co-localized in calcitonin-positive cells.
Localization (co-localized) of NPY associated with calcitonin gene-related peptide
6) Confidence 0.73 Published 1992 Journal Acta Pathol. Jpn. Section Abstract Doc Link 1609616 Disease Relevance 0.95 Pain Relevance 0.52
Neuropeptide Y release occurs mainly upon high stimulation frequencies or during strong sympathetic reflex activation in animals and humans.
Localization (release) of Neuropeptide Y in sympathetic associated with neuropeptide
7) Confidence 0.71 Published 1987 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2455193 Disease Relevance 0.17 Pain Relevance 0.49
Guanethidine inhibits the NPY release from sympathetic nerve terminals. alpha 2-Adrenoceptor agonists like clonidine inhibit the nerve stimulation-evoked NPY release and treatment with clonidine elevates the tissue content of NPY.
Localization (release) of NPY in sympathetic associated with guanethidine, agonist and clonidine
8) Confidence 0.71 Published 1987 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2455193 Disease Relevance 0.40 Pain Relevance 0.78
Localization of neuropeptide Y Y1 receptor mRNA in human tooth pulp.
Localization (Localization) of neuropeptide Y in tooth pulp associated with neuropeptide
9) Confidence 0.70 Published 1998 Journal Arch. Oral Biol. Section Title Doc Link 9681114 Disease Relevance 0 Pain Relevance 0.18
These results suggest that the released NPY may be the mediator of the adrenoceptor antagonist- and reserpine-resistant functional responses to SNS in the gracilis muscle.
Localization (released) of NPY in gracilis associated with antagonist
10) Confidence 0.70 Published 1988 Journal Acta Physiol Scand Suppl Section Abstract Doc Link 3232527 Disease Relevance 0.08 Pain Relevance 0.27
Neurochemicals commonly reported in the vLGN and IGL are neuropeptide Y, GABA, enkephalin, and nitric oxide synthase (localized in cells) and serotonin, acetylcholine, histamine, dopamine and noradrenalin (localized in fibers).
Localization (localized) of neuropeptide Y in IGL associated with dopamine, gaba, neuropeptide, enkephalin and serotonin
11) Confidence 0.68 Published 1997 Journal Neurosci Biobehav Rev Section Abstract Doc Link 9353800 Disease Relevance 0 Pain Relevance 0.34
No significant changes in cardiac neuropeptide Y release or in central monoamine turnover were demonstrated.
Localization (release) of neuropeptide Y associated with neuropeptide and monoamine
12) Confidence 0.68 Published 2003 Journal Hypertension Section Abstract Doc Link 12623958 Disease Relevance 0.36 Pain Relevance 0.65
MEAGL and NPY were co-localized in some adrenal medullary cells.
Localization (localized) of NPY
13) Confidence 0.68 Published 1987 Journal Peptides Section Abstract Doc Link 2883635 Disease Relevance 0.43 Pain Relevance 0.43
Other neuropeptides have been isolated, including galanin, neuropeptide Y, bombesin, gastrin releasing peptide, enkephalins and katacalcin.
Localization (releasing) of neuropeptide Y associated with neuropeptide and enkephalin
14) Confidence 0.68 Published 1989 Journal Rev Pneumol Clin Section Abstract Doc Link 2576326 Disease Relevance 0.15 Pain Relevance 0.70
Immunohistochemical localization of substance P (SP), CGRP, VIP, neuropeptide Y (NPY), and somatostatin (SOM) in the carotid labyrinth were compared in some species of amphibians using the peroxidase-antiperoxidase method.
Localization (localization) of neuropeptide Y in labyrinth associated with somatostatin, neuropeptide and substance p
15) Confidence 0.68 Published 1991 Journal Histochemistry Section Abstract Doc Link 1717415 Disease Relevance 0 Pain Relevance 0.56
Growing evidence is showing that allergic reactions are influenced by the peripheral nervous system through the release of neuromediators including substance P (SP), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and calcitonine gene-related peptide (CGRP) [1-5].
Localization (release) of NPY in peripheral nervous system associated with peripheral nervous system, hypersensitivity, neuropeptide and substance p
16) Confidence 0.65 Published 2011 Journal Molecular Vision Section Body Doc Link PMC3021574 Disease Relevance 0.55 Pain Relevance 0.42
It has been widely demonstrated that SP, NPY, and CGRP are released from nerve endings at inflammatory sites and, more recently, a role of VIP at the sites of neurogenic inflammation has also been demonstrated in both animal models and humans [6-9].
Localization (released) of NPY in nerve associated with inflammation, neurogenic inflammation and substance p
17) Confidence 0.65 Published 2011 Journal Molecular Vision Section Body Doc Link PMC3021574 Disease Relevance 0.72 Pain Relevance 0.45
Growing evidence is showing that allergic reactions are influenced by the peripheral nervous system through the release of neuromediators including substance P (SP), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and calcitonine gene-related peptide (CGRP) [1-5].
Localization (release) of neuropeptide Y in peripheral nervous system associated with peripheral nervous system, hypersensitivity, neuropeptide and substance p
18) Confidence 0.65 Published 2011 Journal Molecular Vision Section Body Doc Link PMC3021574 Disease Relevance 0.55 Pain Relevance 0.42
Neuropeptide Y is colocalized in adrenergic vasoconstrictor neurons, whereas vasoactive intestinal polypeptide is colocalized in cholinergic sudomotor neurons.
Localization (colocalized) of Neuropeptide Y in neurons associated with neuropeptide
19) Confidence 0.61 Published 1994 Journal Ann. Neurol. Section Abstract Doc Link 8024263 Disease Relevance 0.19 Pain Relevance 0.59
It is suggested that NPY is released mainly at high levels of sympathetic activity and that blood-pressure-lowering drugs acting on alpha adrenoceptors acutely influence the release of both NA and NPY-LI from sympathetic nerves in humans.
Localization (release) of NPY in sympathetic associated with noradrenaline
20) Confidence 0.59 Published 1988 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2468060 Disease Relevance 0 Pain Relevance 0.60

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox